ArticleFrontiers in oncology2026
The impacts of androgen receptor on treatment response and survival in triple-negative breast cancer treated with neoadjuvant chemotherapy: a single-center retrospective study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, resulting in limited treatment options. The present study explored the association between androgen receptor (AR) expression and clinicopathological features, as well as its impact on response to neoadjuvant chemotherapy (NACT) and its prognostic and predictive value in patients with TNBC. Method: In this single-center, retrospective study, we considered the data from 81 TNBC patients undergoing post-NACT surgery between January 1, 2017, and January 1, 2023, at the Ankara Oncology Health Application and Research Center of Health Sciences University (SUAM). Patients were grouped by their AR expression status and compared by clinicopathological features, treatment responses, and survival outcomes. Results: We detected AR positivity in 20 patients (26%) but found no significant association between AR expression and patients' demographics. Yet, AR positivity was significantly associated with post-NACT axillary lymph node metastasis (p = 0.017), and the complete axillary response was significantly more prevalent in AR-negative patients (p = 0.002). Pre- and post-NACT Ki-67 values were significantly higher in the AR-negative group (p < 0.001 and p = 0.024, respectively). The findings showed no significant impact of AR status on disease-free survival (DFS) and overall survival (OS) (p = 0.132 and p = 0.079, respectively). Conclusion: Overall, we concluded that AR negativity was linked to increased proliferative activity and complete axillary response in TNBC patients. AR positivity, on the other hand, was associated with residual nodal disease. Ultimately, we could show no significant influence of AR expression on survival. Our findings suggest that AR may serve as a potential biomarker for predicting axillary response in TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.